正在进行的关于免疫疗法在晚期卵巢癌 (OC) 中的作用的研究和当前的临床试验表明，患者对免疫检查点抑制剂 (ICI) 单一疗法的反应有限。当与其他治疗或药物联合使用时，免疫治疗的疗效将会显着提高。生物标志物可用于识别反应较好的患者，从而提高免疫治疗的精确度和疗效。晚期 OC 的关键生物标志物包括同源修复缺陷、程序性死亡配体 (PD-L) 1 表达、趋化因子和肿瘤浸润淋巴细胞。这些生物标志物将来可以用于选择最合适的患者群体。本综述从基因组学、转录组学和蛋白质组学三个组学角度全面考察了 OC 免疫治疗生物标志物的研究和开发，这可能为 OC 免疫治疗策略的有效性提供指导。© 2024。作者，独家许可Springer Science Business Media, LLC，隶属于 Springer Nature。

The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatments or drugs, the efficacy of immunotherapy will be significantly improved. Biomarkers can be used to identify patients with better responses, thereby improving the precision and efficacy of immunotherapy. Key biomarkers for advanced OC include homologous repair deficiency, programmed death-ligand (PD-L) 1 expression, chemokines, and tumor infiltrating lymphocytes. These biomarkers could be applied in the future to select the most suitable patient populations. This review comprehensively examines the research and development of biomarkers in OC immunotherapy from three omics perspectives: genomics, transcriptomics, and proteomics, which may provide guidance for the effectiveness of OC immunotherapy strategies.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.